Weigao Orthopaedics Acquires Loss-Making Endoscopy Firm Jiesibai'er for RMB 86.46 Million to Strengthen Minimally Invasive Portfolio
WEGO ORTHO
Orthopedic Medical Device Manufacturer
Jiesbyer Medical
Developer of Percutaneous Spinal and Orthopedic Endoscopic Technologies and Products
Intelligent Medical Device Network NewsRecently, according to an announcement by WEGO ORTHO,The company plans to“R&D Center Construction Project”Unused portion of the raised funds in China8646RMB million for the acquisition of Suzhou Jiesbyer Medical Technology Co., Ltd. (hereinafter referred to as“Jiesbyer Medical”) Partial equity and capital increase for Jiesbyer Medical, while Jiesbyer Medical is currently in a loss.
ForR&D Center Construction Project”Specific Reasons for the Proposed Change, according to WEGO ORTHO, the first isProactively respond to industry policy changes and accelerate strategic layout.：
According toWEGO ORTHOIntroduction, Original Company“R&D Center Construction Project”The project planning was formed relatively early. After the company went public, the spinal, trauma, joint, and sports medicine products originally covered by the R&D center project were gradually included in the centralized procurement scope, which had a certain impact on the industry and the company’s business expansion and R&D planning.
In response to the industry policies such as centralized procurement and changes in the R&D direction of the orthopedic industry,WEGO ORTHOThe addition of implementation sites in Shanghai and Wuhan has been completed. The current focus of this fundraising project is to advance minimally invasive orthopedic products and powered products.3DTechnological breakthroughs and product innovations in high value-added production lines such as printing and craniomaxillofacial repair.
Data shows,Jiesbyer Medical focuses on the fields of spinal minimally invasive and sports medicine, with expertise in orthopedic minimally invasive and active energy devices.
Large Technology Platform: The main products include percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone scalpels, medical endoscope camera systems, high-frequency electrosurgical units, and various supporting instruments and consumables. The company has strong R&D capabilities in the two major product fields of minimally invasive orthopedic products and powered energy products.
Mr. Hu Shanyun, the founder of Jiesbyer Medical, has many years of experience in the medical device industry and has mastered the core R&D and production technologies of Jiesbyer's minimally invasive orthopedic and powered energy platforms. After years of technical R&D accumulation, Jiesbyer Medical’s main products that have obtained certifications include spinal endoscopes, arthroscopes, optical scopes, and other minimally invasive orthopedic products, as well as high-frequency electrosurgical units, ultrasonic bone scalpels, surgical power systems, and other powered products, forming a relatively complete product portfolio.
In addition, Jiesbyer Medical's related products have certain leading advantages in technology research and development, such as2025Year7The bone tissue surgical device (i.e., ultrasonic osteotome) that obtained certification this month has completed the integration of the foot pedal and the single-unit integrated mirror./An integrated design of open ultrasound, high-speed power, high-speed resection, perfusion pump, and negative pressure pump ensures continuous flow while keeping the surgical area pressure within a safe range; in terms of spinal endoscopy and arthroscopy, Jiesbyer Medical is a Chinese manufacturer that fully independently masters the design, research, and production of various types of optical and electronic endoscopes.
Therefore, Jiesbyer Medical has deep accumulation in the two major technical platforms of minimally invasive orthopedics and active energy devices.“R&D Center Construction Project”The key development direction of minimally invasive orthopedic products and active products has strong synergy, which can strengthen the company's technical accumulation in high-frequency electrosurgical devices, surgical power systems, and ultrasonic osteotomes, and further enhance the company's advantages in minimally invasive spinal and arthroscopic products.
Against the backdrop of the continuous deepening and advancement of the orthopedic centralized procurement policy,WEGO ORTHOIt is necessary to actively adjust development strategies to seize new market opportunities. The acquisition of Jiesbyer Medical's equity and the subsequent capital increase will directly grant access to its two mature product lines—minimally invasive orthopedics and active energy platforms—as well as their production capabilities. This will enable the company to accelerate its entry into high-growth business areas, effectively counteract pricing pressures from centralized procurement on traditional products, and leverage the increased market concentration brought by centralized procurement to rapidly achieve import substitution, resulting in a dual improvement in market share and sales profitability.
WEGO ORTHOStated that, under the industry background of the continuous deepening and advancement of the orthopedic centralized procurement policy, the company needs to actively adjust its development strategy to seize new market opportunities. The acquisition of Jiesbyer Medical's equity and the subsequent capital increase will directly grant access to its two mature product lines—orthopedic minimally invasive and active energy platforms—as well as their production capabilities. This enables the company to accelerate its entry into high-growth business areas, effectively counteract the pricing pressures on traditional products caused by centralized procurement, and leverage the increased market concentration brought by the policy to quickly achieve import substitution, resulting in a dual improvement in market share and sales profitability.
Secondly, it isQuickly acquire key technologies, further grasp the trend of minimally invasive development in the orthopedic industry, expand product coverage to the entire life cycle of spinal diseases as well as the repair and reconstruction of sports injuries, and strengthen core competitiveness.。
With the increasing demand for treatment quality from patients, clinical surgeries are trending towards minimally invasive procedures. The paradigm of orthopedic surgeries has undergone significant changes driven by surgical navigation and endoscopy. Minimally invasive orthopedic surgeries are gradually becoming the primary approach in orthopedic treatment, driving traditional orthopedic surgeries to expand into areas such as sports injury repair and reconstruction, as well as the full life cycle management of spinal diseases. Therefore, minimally invasive orthopedic surgery products represent a key growth area in the future of orthopedics, aligning with the company's established product innovation and strategic development direction.
Currently,WEGO ORTHOIn the orthopedic minimally invasive product line, orthopedic endoscopic products, orthopedic minimally invasive consumables, and energy-based active products have been integrated to form a preliminary overall solution. Jiesbyer Medical has an orthopedic minimally invasive and energy-based active device technology platform. Its main products include percutaneous spinal endoscopes, orthopedic joint endoscopes, ultrasonic bone scalpels, medical endoscopic camera systems, high-frequency electrosurgical units, and various types of grinding heads, drill bits, and other supporting instrument consumables, providing...WEGO ORTHOSupplement for minimally invasive surgical products.
This acquisition will enableWEGO ORTHOQuickly integrate Jiesbyer Medical's advanced technology, mature products, and production processes in the field of minimally invasive orthopedics withWEGO ORTHOThe existing R&D planning creates a strong synergistic effect and rapidly strengthens.WEGO ORTHOWEGO ORTHOIn the core competitiveness of the minimally invasive field, accelerate the formation of an integrated advantage from research and development, production to sales, which is conducive toWEGO ORTHOThe expansion of the product into the full life cycle of spinal diseases and the repair and reconstruction of sports injuries holds significant strategic importance.
The third one isAccelerate the Construction of Fund-raising Projects and Improve the Efficiency of Fund Utilization。
WEGO ORTHO stated,Since its listing, the R&D center construction project of the company has completed the construction at the implementation sites in Shanghai and Wuhan. The R&D directions cover the main product series including spinal, trauma, joint, and sports medicine.
In recent years, under the influence of the orthopedic centralized procurement policy, the company has adjusted its product R&D planning and actively expanded the layout of innovative product lines. However, during the project implementation process, the cycle for innovative products from R&D, clinical trials, registration certification to the eventual achievement of scaled commercial transformation is relatively long, with overall progress slower than expected.
This change involves acquiring and increasing the capital of Jiesbyer Medical, a company that already possesses mature products and production capabilities. It can significantly shorten the new product’s time to market, allowing the raised funds to be converted into productivity and economic benefits more quickly, improving the efficiency of fund utilization, and better safeguarding the interests of all shareholders.
In the future, the company will leverage its mature marketing network system, deep hospital customer resources, and strong brand influence to promote Jiesbyer Medical's products in increasing market penetration and achieving rapid growth. At the same time, the addition of Jiesbyer will also enrich the company’s product portfolio, providing clinical customers with more comprehensive solutions, further enhancing customer loyalty, and jointly exploring broader market opportunities.
This acquisition aims to provide a one-stop solution for clinical use by strengthening the product line, building a mutually supportive and synergistic product ecosystem, ultimately enhancing industry competitiveness and overall profitability, and solidifying the company's leading position in the orthopedic market.
Editor's Express
1
Enterprise interviews, in-depth reporting and promotion of products and technologies, industry report consulting, contributions;
2
Contact: 13714842321 (Same on WeChat)
Previous Review
1
2
3
4